GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » Cyclically Adjusted Book per Share

Plus Therapeutics (Plus Therapeutics) Cyclically Adjusted Book per Share : $453.44 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Plus Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Plus Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $-0.303. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $453.44 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Plus Therapeutics's average Cyclically Adjusted Book Growth Rate was -26.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -48.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -45.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Plus Therapeutics was 92.50% per year. The lowest was -55.10% per year. And the median was -48.40% per year.

As of today (2024-04-27), Plus Therapeutics's current stock price is $1.69. Plus Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $453.44. Plus Therapeutics's Cyclically Adjusted PB Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Plus Therapeutics was 268.48. The lowest was 0.01. And the median was 0.07.


Plus Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Plus Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics Cyclically Adjusted Book per Share Chart

Plus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,789.26 3,266.32 773.97 612.92 453.44

Plus Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 612.92 501.51 441.48 611.67 453.44

Competitive Comparison of Plus Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Plus Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Plus Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's Cyclically Adjusted PB Ratio falls into.



Plus Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Plus Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.303/129.4194*129.4194
=-0.303

Current CPI (Dec. 2023) = 129.4194.

Plus Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 3,431.429 99.695 4,454.543
201406 1,612.162 100.560 2,074.842
201409 -4,221.795 100.428 -5,440.547
201412 -6,131.183 99.070 -8,009.452
201503 -21,882.075 99.621 -28,427.361
201506 1,602.837 100.684 2,060.292
201509 3,378.378 100.392 4,355.226
201512 6,706.593 99.792 8,697.689
201603 4,162.903 100.470 5,362.379
201606 6,857.509 101.688 8,727.616
201609 5,007.326 101.861 6,362.053
201612 3,801.384 101.863 4,829.764
201703 2,322.713 102.862 2,922.396
201706 2,529.279 103.349 3,167.302
201709 1,688.769 104.136 2,098.797
201712 1,686.122 104.011 2,098.015
201803 1,031.630 105.290 1,268.056
201806 577.278 106.317 702.720
201809 393.714 106.507 478.413
201812 264.289 105.998 322.687
201903 132.044 107.251 159.338
201906 -212.458 108.070 -254.431
201909 0.845 108.329 1.010
201912 4.484 108.420 5.352
202003 0.329 108.902 0.391
202006 11.582 108.767 13.781
202009 8.563 109.815 10.092
202012 6.736 109.897 7.933
202103 14.017 111.754 16.233
202106 14.823 114.631 16.735
202109 14.409 115.734 16.113
202112 10.480 117.630 11.530
202203 9.894 121.301 10.556
202206 6.462 125.017 6.690
202209 5.252 125.227 5.428
202212 2.877 125.222 2.973
202303 1.111 127.348 1.129
202306 0.924 128.729 0.929
202309 0.580 129.860 0.578
202312 -0.303 129.419 -0.303

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Plus Therapeutics  (NAS:PSTV) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Plus Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.69/453.44
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Plus Therapeutics was 268.48. The lowest was 0.01. And the median was 0.07.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Plus Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Plus Therapeutics (Plus Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
Executives
Marc H Hedrick officer: President C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Robert P Lenk director LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060
Howard Clowes director 217 DWIGHT ROAD, BURLINGAME CA 94010
Greg Petersen director 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002
Sims Andrew John Hugh Macintyre officer: Chief Financial Officer 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756
Norman D. Lafrance officer: CHIEF MEDICAL OFFICER MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142
Es-johansson An Van director 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
Ag Postfinance 10 percent owner MINGERSTRASSE 20, BERN V8 3030
Bank Sa Swissquote 10 percent owner CHEMIN DE LA CRETAUX 33, GLAND V8 1196
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Ron Martell director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Mark Marino officer: Chief Medical Officer C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
John David Harris officer: VP and GM of Cell Therapy 3020 CALLAN ROAD, SAN DIEGO CA 92121
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Rickey director

Plus Therapeutics (Plus Therapeutics) Headlines